Clinical trial
A Randomized, Multi-Center, Double Blind, 3 Arm, Phase I/II Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
NCT00745511 is registered in ClinicalTrials.gov with Ora Bio Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Multi-Center, Double Blind, 3 Arm, Phase I/II Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
- Lead sponsor
- Ora Bio Ltd.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- March 31, 2009
- Completion date
- June 30, 2010
- Enrollment
- 96 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.